![DSpace logo](/jspui/image/logo.gif)
Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13429
Title: | Antibody–Drug Conjugates: Development and Applications |
Authors: | Taliyan, Rajeev Singhvi, Gautam |
Keywords: | Pharmacy Antibody–drug conjugates (ADCs) Drug |
Issue Date: | Nov-2022 |
Publisher: | Wiley |
Abstract: | Antibody–drug conjugates (ADCs) are relatively newly developed treatments but rapidly growing science. Theoretically, they are like a combination of payload (the drug that is to be delivered; often cytotoxic) and targeted drug-delivery system. In this type of system, the cytotoxic drug undergoes conjugation with a monoclonal antibody via a chemical linker. The fundamental design of ADCs imparts desired properties to the delivery system, such as physiochemical strength, biodegradable nature, and biocompatibility. This plays a crucial role in the management of diseases via offering numerous benefits, such as high drug loading, less incidence of adverse effects, site-specific release, and longer circulation time in the body. In this review, the recent advancements in the preparation of ADCs (including recently approved ADCs), pharmacokinetics, their applications, and regulatory consideration have been summarized. Further, it also provides a discussion on the future status of this therapy for the treatment and management of oncological conditions. |
URI: | https://onlinelibrary.wiley.com/doi/abs/10.1002/9783527827855.ch5 http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13429 |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.